Spherix Global Insights

June 07, 2018

Ocrevus Proves Mettle in Real-World PPMS – Adverse events from ongoing study in line with major trial results

From: MedPage Today
By: Salynn Boyles, Contributing Writer, MedPAge Today

NASHVILLE — Ocrelizumab (Ocrevus), the first and only FDA-approved disease-modifying therapy (DMT) to treat primary progressive multiple sclerosis (PPMS), has lived up to its hype, according to the CEO of the Consortium of Multiple Sclerosis Centers (CMSC).

“Ocrelizumab has really changed the landscape for patients who haven’t had many therapeutic options in the past. I do think that, so far at least, it has lived up to the hype,” June Halper, MSN, told MedPage Today. Ocrelizumab is a humanized, monoclonal antibody that targets CD20+ B cells. FDA approval in 2017 was based on superior efficacy and an acceptable side effect profile demonstrated in three phase III studies…(read more).